The spectrum of synucleinopathies, including Parkinson's disease (PD), multiple system
atrophy (MSA), and dementia with Lewy bodies (DLB), is characterized by α-synuclein …

The emerging role of extracellular vesicles (EVs) in central nervous system (CNS) diseases
is gaining significant interest, particularly their applications as diagnostic biomarkers and …

Seeding activities of disease-associated α-synuclein aggregates (αSynD), a hallmark of
Parkinson's disease (PD), are detectable by seed amplification assay (αSyn-SAA) and being …

The recent development of new methods to detect misfolded α-synuclein (αSyn) aggregates
in biofluids and tissue biopsies in the earliest Parkinson's disease (PD) phases is …

A hallmark event in neurodegenerative diseases is represented by the misfolding,
aggregation and accumulation of proteins, leading to cellular and network dysfunction …

We wish to express our thoughts on recent articles about α-synuclein seed amplification
assays (SAA) from blood-derived neuronal extracellular vesicles (EV) as a potential …

The α-synuclein seed amplification assay (αSyn-SAA) sensitively detects Lewy pathology,
the amyloid state of α-synuclein, in the cerebrospinal fluid (CSF) of patients with Parkinson's …

Progress in dementia research and clinical care has continued to accelerate in 2024.
Monoclonal antibody anti-amyloid immunotherapies (AATs) have been approved for clinical …

Biomarkers that facilitate early detection and track disease progression are an enormous
unmet need in neurodegenerative diseases and their clinical trials. Accurate diagnosis in …

We thank Bernhardt et al. 1 for suggesting a discussion of our recent and earlier publications
2–5 on the use of α-synuclein (α-syn) seed amplification assay (SAA) using blood-derived …